🇺🇸 FDA
Pipeline program

JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

JWCAR029-003

Phase 1 mab completed

Quick answer

JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) for Diffuse Large B Cell Lymphoma is a Phase 1 program (mab) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Shanghai University of Traditional Chinese Medicine
Indication
Diffuse Large B Cell Lymphoma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials